false
0001730430
0001730430
2025-09-03
2025-09-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 3, 2025
Kiniksa
Pharmaceuticals International, plc
(Exact name of Registrant as Specified in Its
Charter)
| England and Wales |
|
001-730430 |
|
98-1795578 |
(State
or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
23 Old Bond Street, Floor 3
London, W1S 4PZ
England,
United Kingdom
(Address of principal executive
offices, including zip code)
(781)
431-9100
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
| Class A
Ordinary Shares, $0.000273235 nominal value |
|
KNSA |
|
The
Nasdaq Stock Market LLC |
| |
|
|
|
(Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
On September 3, 2025, Kiniksa Pharmaceuticals
International, plc (the “Company”) posted an investor presentation (the “Investor Presentation”) to its website
at investors.kiniksa.com. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications,
in connection with its planned presentations to investors, analysts and others.
A copy of the Investor Presentation is furnished with
this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Kiniksa Pharmaceuticals International, plc Investor Presentation |
| |
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC |
| |
|
| Date: September 3, 2025 |
By: |
/s/ Mark Ragosa |
| |
|
Mark Ragosa |
| |
|
Executive Vice President, Chief Financial Officer |
